Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Journal: Current medical research and opinion
Published: January 30, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.
Journal: Journal of geriatric oncology
Published: September 26, 2025
Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.
Journal: Journal of patient-reported outcomes
Published: September 09, 2025
Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Journal: Leukemia & lymphoma
Published: March 23, 2025
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
Journal: The Lancet. Haematology
Published: March 29, 2024
Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.
Journal: Journal of patient-reported outcomes
Published: October 09, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Journal: The New England journal of medicine
Published: July 05, 2023
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 16, 2023
Last Updated: 09/26/2026